Article Text

PDF
Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in chronic obstructive pulmonary disease

Statistics from Altmetric.com

QUESTION

In patients with stable chronic obstructive pulmonary disease (COPD), what are the harms and benefits of inhaled corticosteroid (ICS) therapy?

REVIEW SCOPE

Included studies compared an ICS with placebo or other inhaled medications in patients ⩾40 years of age with stable COPD. Outcomes were all-cause mortality at 1 and 3 years, pneumonia, and fractures.

REVIEW METHODS

Medline, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, CINAHL, Web of Science, and PsycINFO (to Feb 2008); and references were searched for published, double-blind, randomised controlled trials (RCTs) with duration ⩾6 months. 11 RCTs (14 comparisons, n = 14 426) met the selection criteria. 8 comparisons were placebo controlled; most other trials compared an ICS plus a long-acting β2 agonist (LABA) with the LABA …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.